Internal Medicine, Hematology & Oncology · Chicago, IL
NPI
1306026117
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
675 N Saint Clair St, Galter 21-100
Chicago, IL, 60611
Phone (312) 695-0990
Groups this clinician bills Medicare through
Medicare paid, 2024
$479K
17,773 services
Medicare patients, 2024
162
Average age 69
Drug cost, 2024
$1.6M
915 prescriptions
Company payments, 2025
$9,618
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kehinde Adekola was code J1569 (injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg), 740 times for 12 patients. In total Kehinde Adekola billed 17,773 services in 82 codes, and Medicare paid $479K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-09-19.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 740 | 12 | $38.96 | $29K |
| 99232 Hospital E&M - Subsequent | Facility | 198 | 50 | $64.03 | $13K |
| 99215 Office E&M - Established | Office | 141 | 34 | $143.39 | $20K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 108 | 33 | $13.32 | $1,438 |
| 99233 Hospital E&M - Subsequent | Facility | 51 | 22 | $97.59 | $4,977 |
| 99214 Office E&M - Established | Office | 39 | 26 | $100.39 | $3,915 |
| 96413 Chemotherapy Administration | Office | 34 | 28 | $105.04 | $3,571 |
| 96375 Injection Administration | Office | 26 | 18 | $12.44 | $323 |
| 96372 Injection Administration | Office | 25 | 11 | $11.63 | $291 |
| 96366 Intravenous Infusion, Hydration | Office | 22 | 13 | $16.36 | $360 |
| 96365 Intravenous Infusion, Hydration | Office | 15 | 15 | $50.76 | $761 |
| 99239 Hospital Discharge Management | Facility | 14 | 14 | $93.66 | $1,311 |
| 38241 Other Organ Systems | Facility | 13 | 13 | $144.82 | $1,883 |
By year: 2022 $476K for 22,649 services; 2023 $1.2M for 36,334 services; 2024 $479K for 17,773 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kehinde Adekola prescribed most often to Medicare patients was Valacyclovir (Valacyclovir Hcl), with 122 prescriptions and refills. In total Kehinde Adekola wrote 915 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Valacyclovir Valacyclovir Hcl | 122 | 212 | 28 | $5,812 |
| Ursodiol Generic | 107 | 167 | 24 | $8,868 |
| Jakafi Ruxolitinib Phosphate | 53 | 53 | 13 | $713K |
| Posaconazole Generic | 49 | 49 | Under 11 | $92K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 34 | 63 | 11 | $104 |
| Voriconazole Generic | 34 | 36 | Under 11 | $42K |
| Allopurinol Generic | 25 | 29 | Under 11 | $35.25 |
| Rosuvastatin Calcium Generic | 25 | 45 | Under 11 | $248 |
| Fluconazole Generic | 24 | 26 | Under 11 | $885 |
| Pantoprazole Sodium Generic | 22 | 44 | Under 11 | $183 |
| Amlodipine Besylate Generic | 17 | 43 | Under 11 | $123 |
| Prednisone Generic | 17 | 25 | Under 11 | $130 |
| Xospata Gilteritinib Fumarate | 17 | 17 | Under 11 | $275K |
| Magnesium Sulfate Generic | 16 | 16 | Under 11 | $358 |
| Levothyroxine Sodium Generic | 15 | 19 | Under 11 | $124 |
Brand drugs: - claims; generic drugs: 690 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kehinde Adekola $9,618 ($9,618 in general payments such as food, travel and fees) from 3 companies. The largest payer was Incyte Corporation with $8,618.
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation INCY | 9 | $8,618 |
| National Marrow Donor Program | 5 | $1,000 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.